Mizolastine

Oral
Allergic rhinitis, Urticaria

Severe heart disease, history of symptomatic arrhythmias, known or suspected QT prolongation, clinically significant bradycardia, electrolyte imbalance (e.g. hypokalaemia). Severe hepatic impairment. Concomitant use with macrolide antibiotics (e.g. erythromycin), systemic imidazole antifungals (e.g. ketoconazole), other agents that may prolong the QT interval (e.g. Class I and III antiarrhythmics).

Mild to moderate hepatic impairment. Pregnancy and lactation.

Significant: CNS depression; QT prolongation.
Gastrointestinal disorders: Nausea, dry mouth, abdominal pain, dyspepsia, diarrhoea.
General disorders and administration site conditions: Transient asthenia.
Investigations: Increased weight.
Metabolism and nutrition disorders: Increased appetite.
Nervous system disorders: Headache, dizziness, transient drowsiness.

This medicine may cause drowsiness, if affected, do not drive or operate machinery.

Potentially Fatal: Increased plasma concentration with systemic imidazole antifungals (e.g. ketoconazole), and macrolide antibiotics (e.g. erythromycin). Increased risk of QT prolongation with class I and III antiarrhythmics (e.g. amiodarone).

Description: Mizolastine is a non-sedating antihistamine which selectively antagonises the peripheral H₁ receptors. It also has mast-stabilising properties.
Onset: Within 1 hour.
Duration: 24 hours.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: 65%. Time to peak plasma concentration: 1.5 hours.
Distribution: Enters breast milk. Plasma protein binding: Approx 98.4%.
Metabolism: Metabolised via glucuronidation and by the CYP3A4 isoenzyme into inactive hydroxylated metabolites.
Excretion: Elimination half-life: 13 hours.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 65906, Mizolastine. https://pubchem.ncbi.nlm.nih.gov/compound/Mizolastine. Accessed Mar. 25, 2021.

Store below 25°C.

Antihistamines & Antiallergics

R06AX25 - mizolastine ; Belongs to the class of other antihistamines for systemic use.

Anon. Mizolastine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/03/2021.

Buckingham R (ed). Mizolastine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/03/2021.

Joint Formulary Committee. Mizolastine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/03/2021.

Mizollen 10 mg Modified-Release Tablets (Aventis Pharma Limited). MHRA. https://products.mhra.gov.uk. Accessed 04/03/2021.